1. Scrip
  2. >>Archive

Axovant's IPO: Harbinger Of A Biotech Bubble?

 
• By Ed Silverman

In June, Axovant Sciences Ltd. launched an IPO in which its stock almost doubled on the first day of trading and its valuation approached a frothy $3 billion. And this startling performance was attributed to just one asset – an experimental compound for Alzheimer’s disease.

In June, the relatively unknown biotech Axovant Sciences Ltd. launched a $300 million-plus initial public offering in which its stock almost doubled on the first day of trading and its valuation approached a frothy $3 billion. [See Deal] And this startling performance was attributed to just one asset – an experimental compound for Alzheimer’s disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip